To test the effectiveness of antimouse CD25 monoclonal antibody (mAb) against murine renal adenocarcinoma (RENCA) cells, as immunoregulatory/suppressor cells are known to be involved in tumour development in vivo, but the functions of these cells are not yet clear, and eliminating naive CD25 (interleukin-2 receptor α)-positive T cells elicits potent immune responses to syngeneic tumours in vivo.MATERIALS AND METHODS
Aliquots of 1 × 104 or 1 × 105 RENCA cells were implanted into the subcapsule of the left kidney of syngeneic male Balb/c mice. Mice were injected with 125 μg of antimouse CD25 mAb to deplete CD25+ cells before RENCA implantation. Then 104 units of recombinant human interleukin-2 (rhIL-2) were subcutaneously injected twice daily for 7 days. Fourteen or 25 days later the tumour size was determined by laparotomy, and cells sorted using two-colour flow cytometry.RESULTS
Depletion of naive CD25+ cells with anti-CD25 mAb and rhIL-2 administration effectively induced anti-RENCA tumour activity in Balb/c hosts. However, co-administration of anti-CD25 mAb and rhIL-2 abrogated this significant suppression of RENCA tumour growth. RENCA implantation reduced the proportion of CD4+ cells among splenocytes, whereas anti-CD25 mAb treatment increased it. The proportion of CD25+CD8+ cells among splenocytes and that of CD25+ cells among CD8+ cells were markedly reduced by co-administration of anti-CD25 mAb and rhIL-2 with RENCA implantation. Both CD4+ and CD8+ cells were stained around the remnant microscopic RENCA tumour after anti-CD25 mAb treatment.CONCLUSION
Either depletion of naive CD25+ cells or rhIL-2 administration suppressed RENCA tumour growth in murine hosts. However, co-administration of anti-CD25 mAb and rhIL-2 abrogated this significant suppression of RENCA tumour growth.